Why the study?
The efficacy of SGLT2 inhibitors for preventing AF recurrence after catheter ablation in persistent AF patients without class I indications remains uncertain.
Does dapagliflozin reduce AF burden in patients with persistent atrial fibrillation undergoing de novo catheter ablation without standard indications for SGLT2 inhibitors?
Population
Planned 200 PeAF patients undergoing de novo catheter ablation without class I SGLT2i indications
Comparison
Dapagliflozin 10 mg once daily for 3 months vs guideline-directed standard care
Design
Prospective, parallel-group, open-label randomized controlled trial with blinded endpoint evaluation
Follow-up
3 months
Key result
The DARE-AF trial is a planned randomized study to evaluate whether dapagliflozin reduces AF burden at 3 months post-ablation in patients with persistent atrial fibrillation.
Authors
Loading...
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“It is not a problem to use dapagliflozin, but we did not see any effect on early recurrence of AFib. However, we remain very confident about its potential, given that a considerable proportion of patients with atrial fibrillation also have heart failure, particularly heart failure with preserved ejection fraction. We believe that a larger, placebo-controlled trial with an extended follow-up period is warranted to more comprehensively evaluate its potential antiarrhythmic benefits.”
“I think the major limitation of our study is that the treatment of dapagliflozin is short, only three months. So future randomised clinical trials are warranted to test about long-term treatment with SGLT2 inhibitors, maybe one-year treatment of SGLT2 inhibitor could reduce the risk of atrial fibrillation recurrence after catheter ablation.”
DARE-AF will test dapagliflozin for post-ablation AF-burden reduction in persistent AF without diabetes or HF; leaves open extension beyond prior observational data.
RCT (n=200)
Open-label
1:1
Does dapagliflozin reduce AF burden in patients with persistent atrial fibrillation undergoing de novo catheter ablation without standard indications for SGLT2 inhibitors?
The DARE-AF trial will evaluate whether dapagliflozin reduces AF burden after catheter ablation in persistent AF patients without standard indications for SGLT2 inhibitors.
Yang et al. (2026) conducted an RCT in Persistent Atrial Fibrillation (n=200). Dapagliflozin vs. Guideline-directed standard care was evaluated on AF burden, assessed using 7-day single-lead electrocardiogram patches at 3 months after ablation. The DARE-AF trial is a planned randomized study to evaluate whether dapagliflozin reduces AF burden at 3 months post-ablation in patients with persistent atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: